Profile data is unavailable for this security.
About the company
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
- Revenue in CHF (TTM)5.44bn
- Net income in CHF644.00m
- LocationLonza Group AGMuenchensteinerstrasse 38BASEL 4052SwitzerlandCHE
- Phone+41 613168111
- Fax+41 613169111
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|LONN:VTX since |
|Novartis AG-Fill & Finish Facility Stein||Announced||01 Jul 2019||01 Jul 2019Announced||6.98%||--|
|Octane Biotech Inc||Deal completed||29 Oct 2018||29 Oct 2018Deal completed||16.30%||--|
- Top holders